Teresa Brophy Bair Sells 31,487 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 31,487 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81. Following the completion of the transaction, the insider owned 195,444 shares in the company, valued at approximately $2,468,457.72. This represents a 13.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kura Oncology Stock Up 1.5%

Kura Oncology stock opened at $11.89 on Friday. Kura Oncology, Inc. has a fifty-two week low of $7.36 and a fifty-two week high of $12.90. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The firm has a 50 day moving average price of $10.53 and a 200 day moving average price of $9.46. The company has a market capitalization of $1.06 billion, a PE ratio of -3.53 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Research analysts expect that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Analysts Set New Price Targets

KURA has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, June 4th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Finally, Oppenheimer set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.62.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of the company. IFP Advisors Inc increased its stake in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after acquiring an additional 1,284 shares during the period. Allworth Financial LP raised its position in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Kura Oncology by 49.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after acquiring an additional 1,888 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Kura Oncology in the second quarter valued at about $80,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.